Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EUDA
EUDA logo

EUDA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy EUDA Health Holdings Ltd (EUDA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.720
1 Day change
-5.75%
52 Week Range
86.000
Analysis Updated At
2026/04/10
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

EUDA Health Holdings Ltd is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators suggest a bearish trend, and there are no recent positive catalysts or significant trading signals to support immediate investment. Analyst ratings and price target reductions further indicate potential challenges for the company. Holding off on this stock is recommended until stronger signals or positive developments emerge.

Technical Analysis

The MACD is above 0 but positively contracting, indicating weakening bullish momentum. The RSI is neutral at 23.92, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 7.323, with resistance levels at 13.708 and 15.68. Overall, the technical outlook is bearish.

Positive Catalysts

  • NULL identified. No recent news or significant trading trends among hedge funds or insiders.

Neutral/Negative Catalysts

  • Analyst William Gregozeski lowered the price target from $6 to $2.75 due to reduced revenue estimates and share dilution. The bearish moving averages and lack of positive trading signals also weigh against the stock.

Financial Performance

No financial data available for analysis due to data error.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst maintains a Buy rating but significantly lowered the price target to $2.75 from $6, citing reduced revenue estimates and share dilution. This indicates a cautious outlook despite the Buy rating.

Wall Street analysts forecast EUDA stock price to rise
Analyst Rating
0
Wall Street analysts forecast EUDA stock price to rise
Buy
Hold
Sell
0
Current: 7.130
sliders
Low
0
Averages
0
High
0
0
Current: 7.130
sliders
Low
0
Averages
0
High
0
Greenridge
William Gregozeski
Buy
downgrade
$6
AI Analysis
2026-03-09
Reason
Greenridge
William Gregozeski
Price Target
$6
AI Analysis
2026-03-09
downgrade
Buy
Reason
Greenridge analyst William Gregozeski lowered the firm's price target on EUDA Health to $2.75 from $6 and keeps a Buy rating on the shares. The firm updated its model for a reduction of Helixe bottles sold in 2026, decreasing to 50,000 from 105,000, which reduced its revenue estimate to $27.23M from $43.05M. It also added in the 12.5M shares that were issued in late February, which had a dilutive effect on its EPS estimates, the analyst tells investors.

People Also Watch